{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bohringer N"],"funding":["HHS | National Institutes of Health","German Federal Ministry of Education and Research (BMBF) via a project of the Deutsche Zentrum für Infektionsforschung","AntiResist: New approaches to combat antibiotic-resistant bacteria","Swiss National Science Foundation","NIAID NIH HHS"],"pagination":["e0153521"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8694152"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(3)"],"pubmed_abstract":["There is great need for therapeutics against multidrug-resistant, Gram-negative bacterial pathogens. Recently, darobactin A, a novel bicyclic heptapeptide that selectively kills Gram-negative bacteria by targeting the outer membrane protein BamA, was discovered. Its efficacy was proven in animal infection models of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa, thus promoting darobactin A as a promising lead compound. Originally discovered from members of the nematode-symbiotic genus <i>Photorhabdus</i>, the biosynthetic gene cluster (BGC) encoding the synthesis of darobactin A can also be found in other members of the class <i>Gammaproteobacteria</i>. Therein, the precursor peptides DarB to -F, which differ in their core sequence from darobactin A, were identified <i"],"journal":["Microbiology spectrum"],"pubmed_title":["Mutasynthetic Production and Antimicrobial Characterization of Darobactin Analogs."],"pmcid":["PMC8694152"],"funding_grant_id":["180541","51AU40_180541","TTU09.818","187170","R01 AI158388","R01AI158388"],"pubmed_authors":["Modaresi SM","Lewis K","Jakob RP","Iinishi A","Mettal U","Maier T","Schaberle TF","Hiller S","Liu Y","Green R","Marner M","Wuisan ZG","Bohringer N"],"additional_accession":[]},"is_claimable":false,"name":"Mutasynthetic Production and Antimicrobial Characterization of Darobactin Analogs.","description":"There is great need for therapeutics against multidrug-resistant, Gram-negative bacterial pathogens. Recently, darobactin A, a novel bicyclic heptapeptide that selectively kills Gram-negative bacteria by targeting the outer membrane protein BamA, was discovered. Its efficacy was proven in animal infection models of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa, thus promoting darobactin A as a promising lead compound. Originally discovered from members of the nematode-symbiotic genus <i>Photorhabdus</i>, the biosynthetic gene cluster (BGC) encoding the synthesis of darobactin A can also be found in other members of the class <i>Gammaproteobacteria</i>. Therein, the precursor peptides DarB to -F, which differ in their core sequence from darobactin A, were identified <i","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2026-06-10T05:52:57.528Z","creation":"2025-04-05T20:40:20.511Z"},"accession":"S-EPMC8694152","cross_references":{"pubmed":["34937193"],"doi":["10.1128/spectrum.01535-21"]}}